University of Sydney receives AUD 3.75 million (USD 2.5M) to explore avenues for personalized ovarian cancer treatment. The aim is to create a process that analyses the molecular profile of a patient’s cancer and matches the patient to the best clinical trial.
Want to dig deeper into treatment options for cancer?
-
Article
Immunogenic Cell Death: Bench Comes to Bedside…With Caveats
Read Now
J. Milburn Jessup
Global Forum -
Article
New Concepts in Cancer Therapy with Combined Radiation and Drugs
Read Now
C. Norman Coleman
Global Forum -
Article
Favorable-Risk Prostate Cancer in the Age of Precision Medicine
Read Now
William J. Catalona et al.
Global Forum -
Video
The Cholangiocarcinoma Foundation: Accelerating Research to Find a Cure
Watch Now
Melinda Bachini -
Article
What Are the Chances of Getting a Cancer Drug Approved?
Read Now
Chi Heem Wong et al.
Global Forum -
Article
Precision Medicine Advances in Targeted Therapy and Immunotherapy for Patients with Non-Small Cell Lung Cancer
Read Now
Bruce E. Johnson
Global Forum -
Podcast
Translating Clinical Trials into Clinical Benefit
Listen Now
Gary Kelloff, David Parkinson
Global Forum -
Article
21st-Century Oncology Drug Safety via New-Age Regulatory Standards and Practices
Read Now
Peter J. Pitts et al.
Therapeutic Innovation & Regulatory Science
Member-only content